[Animal Modeling]-Ermidine in the pulmonary hypertension model

  Objective: To explore the preventive and therapeutic effects of anitidine (DIZE) on pulmonary hypertension model rats.

  Method: Left lobectomy combined with subcutaneous injection of monochromatic Tallinn protein (MCT) into the abdominal wall to establish a PAH rat model. The control group (group A) and the DIZE control group (group B) were randomly divided into 100 adult male Wistar rats. Group), PAH model group (C group), DIZE treatment PAH model group (D group) and (DIZE + C-16) treatment PAH model group (E group), active fluorescence resonance energy transfer (FRET)) and enzyme-linked immunoassay How to measure and calculate the angiotensin converting enzyme 2 (ACE2) level, serum IL-6 and IL-8, mean pulmonary artery pressure (mPAP), right ventricular hypertension index (RVHI) measured by adsorption assay (ELISA) Proportional thickness to pulmonary artery outer diameter (WT), intimal hyperplasia score, and analysis of pulmonary vascular disease by elastic fiber staining.

  Results: Comparison of RVHI, ACE2 enzyme activity, WT and intimal hyperplasia scores: The difference between group C, D, and E was statistically significant compared with group A (P\u003c0.05), with statistically significant academic significance (P\ u003c0.05). The five groups have statistically significant differences in the overall analysis of each index (P\u003c0.05).

  Conclusion: Elmidin can increase the activity of ACE2 enzyme, effectively reduce mPAP, RVHI and WT, while reducing pulmonary arterioles media hypertrophy and inhibiting pulmonary arterioles intimal hyperplasia. The conclusions of this study provide an experimental basis for the treatment of human PAHs with Hermitin.